Nephros (NASDAQ:NEPH) Trading Down 0.3% – What’s Next?

Nephros Inc. (NASDAQ:NEPH) traded down 0.3% on Tuesday . The company traded as low as $3.51 and last traded at $3.57. 3,966 shares changed hands during trading, a decline of 67% from the average daily volume of 12,140 shares. The stock had previously closed at $3.58.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded Nephros from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, June 18th. One research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $6.00.

Nephros Stock Down 0.3%

The firm has a market capitalization of $38.77 million, a P/E ratio of 51.01 and a beta of 1.51. The business’s 50-day simple moving average is $3.34 and its 200 day simple moving average is $3.77.

Nephros (NASDAQ:NEPH) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.01 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.01. Nephros had a net margin of 4.06% and a return on equity of 7.66%. The firm had revenue of $5.21 million during the quarter, compared to analyst estimates of $5.02 million.

Institutional Trading of Nephros

Several hedge funds have recently added to or reduced their stakes in NEPH. Geode Capital Management LLC lifted its stake in Nephros by 3.2% in the second quarter. Geode Capital Management LLC now owns 93,187 shares of the company’s stock worth $381,000 after purchasing an additional 2,898 shares during the last quarter. Topline Capital Management LLC grew its stake in shares of Nephros by 13.1% during the second quarter. Topline Capital Management LLC now owns 477,449 shares of the company’s stock valued at $1,953,000 after buying an additional 55,360 shares during the last quarter. Dimensional Fund Advisors LP bought a new position in shares of Nephros during the third quarter valued at about $64,000. Citadel Advisors LLC increased its holdings in shares of Nephros by 39.2% in the third quarter. Citadel Advisors LLC now owns 16,545 shares of the company’s stock worth $78,000 after buying an additional 4,655 shares during the period. Finally, Navellier & Associates Inc. purchased a new position in shares of Nephros in the fourth quarter worth about $133,000. 41.10% of the stock is owned by institutional investors.

Nephros Company Profile

Nephros, Inc is a development-stage company specializing in advanced water filtration and purification technologies for medical, laboratory, industrial and defense applications. The company’s core offering centers on proprietary hollow fiber ultrafilters designed to remove bacteria, viruses, endotoxins and particulates from water streams. These ultrafilters are used in hemodialysis systems to protect patient treatment, in pharmaceutical and laboratory environments to ensure water quality and in critical field-deployable units for military and emergency response.

The company’s product portfolio includes standalone filtration cartridges for point-of-use and point-of-entry installations in dialysis clinics and hospitals, as well as bench-top and portable water purification systems.